Related Experiment Video

Updated: Aug 18, 2026

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells
06:23

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells

Published on: November 21, 2025

The renoprotective potential of pentoxifylline in chronic kidney disease

Shuei-Liong Lin1, Wen-Chih Chiang, Yung-Ming Chen

  • 1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.

Journal of the Chinese Medical Association : JCMA
|April 9, 2005
PubMed

Insights

Pentoxifylline shows promise in reducing proteinuria and potentially slowing chronic kidney disease (CKD) progression. Further trials are needed to confirm its long-term benefits for renal outcomes in CKD patients.

Area of Science:

  • Nephrology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) progression is complex, and current treatments, while effective, may not halt it long-term.
  • Multidrug approaches with minimal side effects are needed to stop CKD progression.

Purpose of the Study:

  • To investigate the potential of pentoxifylline, a phosphodiesterase inhibitor, in managing CKD progression.
  • To evaluate pentoxifylline's efficacy in reducing proteinuria and improving renal outcomes.

Main Methods:

  • Review of current interventions for CKD progression.
  • Analysis of pentoxifylline's inhibitory effects on cell proliferation, inflammation, and extracellular matrix accumulation.
  • Examination of existing human studies on pentoxifylline in various nephropathies.

Main Results:

  • Pentoxifylline monotherapy significantly reduces proteinuria in membranous nephropathy.
  • Limited studies indicate pentoxifylline's efficacy in reducing proteinuria in diabetic CKD and lupus nephritis.
  • Pentoxifylline exhibits low toxicity.

Conclusions:

  • Pentoxifylline demonstrates potential as an adjunct therapy for CKD.
  • Further clinical trials are essential to ascertain pentoxifylline's role in improving long-term renal outcomes for CKD patients.

Related Concept Videos

Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...